The principal focus of our efforts is to develop and commercialize treatments
for hereditary angioedema and to identify other disorders that are mediated by
We developed KALBITOR on our own, and since 2010, we have been selling it in the
United States for the treatment of acute attacks of HAE. We are also developing
DX-2930, a fully human monoclonal antibody inhibitor of plasma kallikrein, which
we believe is a candidate to treat HAE prophylactically. The safety,
tolerability, and kallikrein inhibition results of a Phase 1a clinical study in
healthy volunteers support advancing the DX-2930 development program into a
Phase 1b study in HAE patients in mid-2014.
We have also completed development of a biomarker assay that should assist us in
detecting the activation of plasma kallikrein in patient blood.